BSG and neoplasm: CAR T-cells targeted against CD147 have achieved anti-tumour activity in pre-clinical models of hepatocellular carcinoma, employing doxycycline inducibility [166] or SynNotch technology [167] to mitigate on-target off-tumour toxicity.